Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial.

[1]  Jack Cuzick,et al.  Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor–Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5 , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Daniel F. Hayes,et al.  20‐Year Risks of Breast‐Cancer Recurrence after Stopping Endocrine Therapy at 5 Years , 2017, The New England journal of medicine.

[3]  C. Seynaeve,et al.  Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[4]  S. Paik,et al.  Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Proje , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  T. Whelan,et al.  Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. , 2016, The New England journal of medicine.

[6]  R. Greil,et al.  The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer , 2014, Clinical Cancer Research.

[7]  R. Greil,et al.  The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients , 2013, British Journal of Cancer.

[8]  Jack Cuzick,et al.  Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. , 2013, The Lancet. Oncology.

[9]  Yi Zhang,et al.  Prediction of Late Disease Recurrence and Extended Adjuvant Letrozole Benefit by the HOXB13/IL17BR Biomarker , 2013, Journal of the National Cancer Institute.

[10]  Ming-Feng Hou,et al.  Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial , 2013, The Lancet.

[11]  A. Ocaña,et al.  Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. , 2011, Journal of the National Cancer Institute.

[12]  R. High,et al.  Alternatives to the standard Fleming, Harrington, and O’Brien futility boundary , 2011, Clinical trials.

[13]  J. Costantino,et al.  Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Sally Hunsberger,et al.  Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Jun Yan.  Survival Analysis: Techniques for Censored and Truncated Data , 2004 .

[16]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[17]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[18]  Z. Ying,et al.  Checking the Cox model with cumulative sums of martingale-based residuals , 1993 .

[19]  J. Kalbfleisch,et al.  The Statistical Analysis of Failure Time Data , 1980 .

[20]  P. O'Brien,et al.  A multiple testing procedure for clinical trials. , 1979, Biometrics.

[21]  L. Freedman,et al.  Allocation of patients to treatment groups in a controlled clinical study. , 1978, British Journal of Cancer.

[22]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[23]  C. Velde,et al.  Systematic review of the clinical and economic value of gene expression profiles for invasive early breast cancer available in Europe. , 2018, Cancer treatment reviews.

[24]  P. Neven,et al.  Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[25]  H. Putter,et al.  Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05) , 2018, Journal of the National Cancer Institute.

[26]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .